No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Guggenheim Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $5
Century Therapeutics Is Maintained at Buy by Guggenheim
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
Century Therapeutics Reports 2024 Financial Results and Strategic Updates
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $2
William Blair Maintains Century Therapeutics(IPSC.US) With Hold Rating